Alterity Therapeutics Ltd
ATHE5.225USD
+0.215+4.29%
Market hours （ET）Quotes delayed by 15 min
46.33MMarket Cap
--P/E TTM
More Details of Alterity Therapeutics Ltd Company
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Company Info
Ticker SymbolATHE
Company nameAlterity Therapeutics Ltd
IPO dateMar 28, 2000
CEODr. David A. Stamler, M.D.
Number of employees10
Security typeDepository Receipt
Fiscal year-endMar 28
AddressL 3 460 Bourke St
CityMELBOURNE
Stock exchangeNASDAQ Capital Market Consolidated
CountryAustralia
Postal code3000
Phone61393494906
Websitehttps://alteritytherapeutics.com/
Ticker SymbolATHE
IPO dateMar 28, 2000
CEODr. David A. Stamler, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Brian Derek Meltzer
Mr. Brian Derek Meltzer
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Mr. Geoffrey Paul Kempler
Mr. Geoffrey Paul Kempler
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Brian Derek Meltzer
Mr. Brian Derek Meltzer
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Mr. Geoffrey Paul Kempler
Mr. Geoffrey Paul Kempler
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Jul 20
Updated: Sun, Jul 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Point72 Asset Management, L.P.
0.86%
Morgan Stanley & Co. LLC
0.28%
Greenleaf Trust
0.11%
UBS Financial Services, Inc.
0.08%
BNP Paribas Securities Corp. North America
0.06%
Other
98.60%
Shareholders
Shareholders
Proportion
Point72 Asset Management, L.P.
0.86%
Morgan Stanley & Co. LLC
0.28%
Greenleaf Trust
0.11%
UBS Financial Services, Inc.
0.08%
BNP Paribas Securities Corp. North America
0.06%
Other
98.60%
Shareholder Types
Shareholders
Proportion
Hedge Fund
0.86%
Research Firm
0.35%
Bank and Trust
0.11%
Investment Advisor
0.09%
Private Equity
0.04%
Other
98.56%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
25
222.41K
1.45%
+22.59K
2025Q1
25
242.89K
1.60%
+14.64K
2024Q4
25
125.35K
1.13%
-75.38K
2024Q3
25
113.89K
1.28%
-62.37K
2024Q2
24
79.19K
0.91%
-96.76K
2024Q1
24
95.17K
1.09%
-51.08K
2023Q4
23
88.25K
1.89%
-31.21K
2023Q3
26
59.08K
1.45%
-63.37K
2023Q2
27
58.44K
1.44%
-90.15K
2023Q1
26
93.79K
2.31%
-17.38K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Point72 Asset Management, L.P.
131.43K
0.86%
+98.80K
+302.83%
Mar 31, 2025
Morgan Stanley & Co. LLC
43.63K
0.29%
-700.00
-1.58%
Mar 31, 2025
UBS Financial Services, Inc.
13.00K
0.09%
+12.62K
+3286.46%
Mar 31, 2025
BNP Paribas Securities Corp. North America
9.75K
0.06%
+962.00
+10.94%
Mar 31, 2025
Twin Lakes Capital
5.92K
0.04%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.16K
0.01%
--
--
May 31, 2025
Osaic Holdings, Inc.
181.00
0%
--
--
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
130.00
0%
+130.00
--
Mar 31, 2025
55IP
53.00
0%
+53.00
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Date
Type
Ratio
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
